Plasma concentration of hGH and anti-hGH antibodies after subcutaneous administration of hGH for 3 weeks to immunosuppressed pigs

Journal of Pharmacological and Toxicological Methods

Volumn 41, Issue 1, 1999, Pages 1-8

  Agersø, Henrik ^a   Wilken, Michael ^a   Drustrup, Jørn ^a   Haahr, Poul Martin ^a   Jørgensen, Karin Damm ^b  

^a NOVO NORDISK A S   (Denmark)

^b LAB Research Denmark   (Denmark)

Author keywords

Anti hGH; Antibodies; Immunosuppressant treatment; Immunosuppressed pig model; Pharmacokinetics

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; GROWTH HORMONE ANTIBODY; HUMAN GROWTH HORMONE; PREDNISOLONE;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE COUNT; NONHUMAN; ORAL DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION; SUSTAINED RELEASE FORMULATION; SWINE;

ANIMALS; ANTIBODY FORMATION; AREA UNDER CURVE; AUTOANTIBODIES; AZATHIOPRINE; CYCLOSPORINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMAN GROWTH HORMONE; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, SUBCUTANEOUS; LEUKOCYTE COUNT; PREDNISOLONE; SWINE;

SUS SCROFA;

EID: 0032832104     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8719(99)00017-9     Document Type: Article

References (11)

1. Andreoni K.A., Odonnell C.P., Burdick J.F., Robotham J.L. Hepatic and renal blood-flow responses to a clinical dose of intravenous cyclosporine in the pig. Immunopharmacology. 28:1994;87-94.
2. de Muinck Keizer-Schrama S., Rikken B. Growth hormone deficiency. Groeihormoondeficientie: diagnostiek en behandeling Tijdschrift Voor Kindergeneeskunde. 60:1992;147-154.
3. Dorchy H., Duchateau J., Bosson D., D'Hooge D. Transfer from purified porcine insulins to semisynthetic human insulins decreases insulin antibodies and circulating immune complexes in diabetic children and adolescents. A two-year follow- up. Diabete Metab. 15:1989;107-110.
4. Emlen W., Mannik M. Effect of preformed immune complexes on the clearance and tissue localization of single-stranded DNA in mice. Clin Exp Immunol. 40:1980;264-272.
5. Gottschalk U., Garnett M.C., Ward R.K., Maibucher A., Kohnlein W. Increased serum stability and prolonged biological half-life of neocarzinostatin covalently bound to monoclonal antibodies. J Antibiot. 44:1991;1148-1154.
6. Johnson O.L., Cleland J.L., Lee H.J., Charnis M., Duenas E., Jaworowicz W., Shepard D., Shahzamani A., Jones A.J., Putney S.D. A month-long effect from a single injection of microencapsulated human growth hormone. Nature Med. 2:1996;795-799.
7. Johnson O.L., Jaworowicz W., Cleland J.L., Bailey L., Charnis M., Duenas E., Wu C., Shepard D., Magil S., Last T., Jones A.J., Putney S.D. The stabilization and encapsulation of human growth hormone into biodegradable microspheres. Pharm Res. 14:1997;730-735.
8. Lee H.J., Riley G., Johnson O., Cleland J.L., Kim N., Charnis M., Bailey L., Duenas E., Shahzamani A., Marian M., Jones A.J., Putney S.D. In vivo characterization of sustained-release formulations of human growth hormone. J Pharmacol Exp Ther. 281:1997;1431-1439.
9. Rehlaender B.N., Cho M.J. Antibodies as carrier proteins. Pharm Res. 15:1998;1652-1656.
10. Tsao P.W., Ito S., Wong P.Y., Radde I.C., Bryson S., Young D.S., Caspi J., Diaz R.J., Martell M.F., Augustine J.M., Wilson G.J., Coles J.G. Pharmacodynamics and pharmacokinetics of cyclosporine-a in the newborn pig. Dev Pharmacol Ther. 18:1992;20-25.
11. Van Haeften T.W., Bolli G.B., Dimitriadis G.D., Gottesman I.S., Horwitz D.L., Gerich J.E. Effect of insulin antibodies and their kinetic characteristics on plasma free insulin dynamics in patients with diabetes mellitus. Metabolism. 35:1986;649-656.